Fig. 5. Serum VEGF-C correlates with antitumor immune responses and PFS after immunotherapy in human metastatic melanoma patients. Serum VEGF-C correlates.

Slides:

Advertisements

Similar presentations

T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia by Michael Kalos, Bruce.

Advertisements

Fig. 1 CSF1 is increased in blood of melanoma patients and correlates with disease progression. CSF1 is increased in blood of melanoma patients and correlates.

Fig. 6. Transgenic expression of αLNNd and mag in dyW/dyW mice improves muscle function, increases body weight, and prolongs life span. Transgenic expression.

LTB4 production is elevated in preclinical and clinical lymphedema

Fig. 4. Primary human metastatic melanomas contain CCL21-expressing LECs, and expression of VEGFC positively correlates with hallmarks of tumor inflammation.

Fig. 7. Gradient of adipocyte size and FAI around the human coronaries in the presence or absence of coronary atherosclerosis. Gradient of adipocyte size.

Fig. 2 LYM attractor metagene.

Fig. 6. dAST directly from clinical samples using dPCR and dLAMP for quantification. dAST directly from clinical samples using dPCR and dLAMP for quantification.

Fig. 5. Correlation between CD34+CD45RA−CD90+ cell dose, engraftment success, and onset of neutrophil/platelet recovery in nonhuman primates. Correlation.

Fig. 3. Cytokines trigger proliferation and block differentiation of perivascular adipocytes. Cytokines trigger proliferation and block differentiation.

Fig. 5. Circulating PPi concentration does not correlate with severity of calcification phenotype in mice. Circulating PPi concentration does not correlate.

Fig. 3 Urinary LAM concentration predicted pulmonary TB and correlated to mycobacterial burden and weight loss. Urinary LAM concentration predicted pulmonary.

Fig. 8. Gene and protein changes in ALK-dependent STING pathways in human sepsis. Gene and protein changes in ALK-dependent STING pathways in human sepsis.

Fig. 5. Correlation of tail and long bone growth velocities with Cxm serum concentrations in mice. Correlation of tail and long bone growth velocities.

Fig. 2. VEGF-C/VEGFR-3 signaling increases responsiveness of melanoma to immunotherapy. VEGF-C/VEGFR-3 signaling increases responsiveness of melanoma to.

Fig. 2. In vitro profiling of tEV markers on cell line–derived EVs.

Fig. 8. In vivo suppression of MM by CMLD

Fig. 2 Maraba treatment results in complete responses in the window of opportunity setting. Maraba treatment results in complete responses in the window.

Fig. 6. Increased efficacy of immunotherapy in lymphangiogenic B16 melanomas depends on CCR7 signaling before therapy and local activation and expansion.

Maraba treatment sensitizes 4T1 tumors to immune checkpoint blockade

CAR8 failure in an OT1 TCR transgenic T cell after exposure to OVA

Fig. 2. GPC3 expression in normal and tumor tissues.

Fig. 5. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic mice. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic.

Fig. 5 A competent Fc is required for the antitumor immune response.

Fig. 2 Systemically released inflammatory factors directly affect HSC-e cell fate. Systemically released inflammatory factors directly affect HSC-e cell.

Fig. 4 CXCL4 potentiates TLR8-mediated activation of SSc pDCs.

Fig. 5. In vivo characterization of adipogenesis by CT.

Fig. 5 Combination intravenous reovirus and checkpoint inhibition in an orthotopic syngeneic brain tumor model. Combination intravenous reovirus and checkpoint.

Fig. 6. Safety assessment in cynomolgus monkey.

Fig. 2. Vascular inflammation blocks perivascular adipocyte differentiation through paracrine signals. Vascular inflammation blocks perivascular adipocyte.

Persistence of CAR4 cells is reduced after sustained TCR engagement

Fig. 4. Restriction of TCR antigen to hematopoietic tissues does not prevent CAR8 exhaustion and failure of leukemia clearance. Restriction of TCR antigen.

Fig. 7 BRD0705 impairs colony formation in AML cell lines and patient cells and shows in vivo efficacy in multiple AML mouse models. BRD0705 impairs colony.

Fig. 4 DMF enhances VSVΔ51 therapeutic efficacy in syngeneic and xenograft tumor models. DMF enhances VSVΔ51 therapeutic efficacy in syngeneic and xenograft.

Fig. 4. Analysis of T cell responses according to treatment and in peptide-treated C-peptide responders and nonresponders. Analysis of T cell responses.

Fig. 8 Combining M7824 with radiation or chemotherapy enhances antitumor efficacy. Combining M7824 with radiation or chemotherapy enhances antitumor efficacy.

Fig. 4. Improved tumor response to docetaxel in TNBC and trastuzumab in HER2-amplified PDX models with the addition of S Improved tumor response.

Fig. 4 TNF-α up-regulates Fas/Fap-1 expression to promote IL-1RA–sEV release in murine MSCs. TNF-α up-regulates Fas/Fap-1 expression to promote IL-1RA–sEV.

Fig. 1 CpG induces the expression of OX40 on CD4 T cells.

Fig. 6. pKL cells revert hyperglycemia in NOD mice in vivo.

Molecular Therapy - Oncolytics

Fig. 2 Analysis of CLL lymph nodes.

Fig. 7. mRIPO therapy restricts tumor growth and produces antigen-specific antitumor immunity. mRIPO therapy restricts tumor growth and produces antigen-specific.

Fig. 2. Exposure of both TCR and CAR antigens diminishes efficacy of CAR8 but not CAR4 cells. Exposure of both TCR and CAR antigens diminishes efficacy.

Fig. 3 Agonists of innate immunity are effective only when released locally from the hydrogel. Agonists of innate immunity are effective only when released.

Fig. 6. CXM correlates with age and growth velocity.

Fig. 3 CSF1 is expressed in human melanoma.

Fig. 7 Vaccine-induced influenza-specific B cells are not maintained in peripheral blood. Vaccine-induced influenza-specific B cells are not maintained.

Fig. 1. Exposure to P. duboscqi uninfected sand flies (USFs) induces an anti-saliva immunity that protects NHP from vector-transmitted CL. Exposure to.

IIV induces CD21hiCD27+ and CD21loCD27+ influenza-specific B cells

Fig. 5 Extended local release of R848 increases the number of innate and adaptive antitumor immune cells and cytokines. Extended local release of R848.

Figure 3 Cytokine gene expression in PBMC stimulated with PPD or MBP in vitroCytokine messenger RNA transcripts were isolated from peripheral blood mononuclear.

Fig. 5 Early and modest immune response at day 3 after exposure in Delayed animals. Early and modest immune response at day 3 after exposure in Delayed.

CSF1 secretion by melanoma cells is induced by CTL-derived cytokines

Fig. 5 A competent Fc is required for the antitumor immune response.

Volume 16, Issue 12, Pages (December 2008)

Fig. 3. Improved clinical responses to CD19 CAR-T cell immunotherapy after Cy/Flu lymphodepletion. Improved clinical responses to CD19 CAR-T cell immunotherapy.

Targeting CD47 in Sézary syndrome with SIRPαFc

BMS blocks functional responses in primary immune cells driven by IFNα

Fig. 1. Detection of circulating tumor DNA in CRPC patients.

Fig. 4. Long-term persistence of CTL019 cells and polyfunctionality in patients achieving CR. Long-term persistence of CTL019 cells and polyfunctionality.

Combined BRAFi and anti-CTLA4 administration leads to prolonged antitumor immunity in a patient with metastatic melanoma. Combined BRAFi and anti-CTLA4.

Fig. 2 Extended local release of agonists of innate immunity prevents tumor recurrence and eliminates distal metastases. Extended local release of agonists.

MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma by Scott J. Rodig, Daniel Gusenleitner, Donald.

Fig. 2. PlGF-2123–144 conjugation reduces systemic exposure to checkpoint blockade Abs and potential treatment-related toxicity. PlGF-2123–144 conjugation.

Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia by David L. Porter, Wei-Ting.

A to C, MetMAb shows strong antitumor activity in the KP4 orthotopic model of pancreatic cancer by ultrasound. A to C, MetMAb shows strong antitumor activity.

Correlation of PTEN loss in melanoma cells with an immune resistance phenotype. Correlation of PTEN loss in melanoma cells with an immune resistance phenotype.

Fig. 5 Proportions of EpCAM+ systemic tumor cells correlate with the clinical outcome of patients with MBC. Proportions of EpCAM+ systemic tumor cells.

Antibody-mediated blockade of the immune-inhibitory PD-1–PD-L1 signaling pathway prolongs survival in poly(I:C)-treated mice. Antibody-mediated blockade.

Presentation transcript:

Fig. 5. Serum VEGF-C correlates with antitumor immune responses and PFS after immunotherapy in human metastatic melanoma patients. Serum VEGF-C correlates with antitumor immune responses and PFS after immunotherapy in human metastatic melanoma patients. (A to C) Correlations of magnitude and quality of T cell responses with serum VEGF-C concentrations (n = 20) in patients enrolled in a phase 1 clinical study (NCT00112229) evaluating an antitumor Melan-A/MART-1 peptide vaccine. T cell responses reflect peak values across four weekly blood samples in Melan-A tetramer+ CD8+ T cells, and serum VEGF-C was measured before therapy. (A) Antigen-specific T cells as % of circulating CD8+ T cells versus serum VEGF-C. Left: Absolute values for each patient (dotted line indicates mean VEGF-C). Right: Comparison of T cell numbers in patients with low (<mean) versus high (>mean) VEGF-C. (B) IFN-α expression and (C) polyfunctionality in terms of IFN-α, TNF-α (tumor necrosis factor–α), IL-2 (interleukin-2), and CD107 expression in tetramer+ CD8+ T cells. (D) PFS of human melanoma patients (n = 76) enrolled in a phase 2 clinical study (NCT01927419) receiving combined αPD-1 and αCTLA-4 checkpoint blockade. Patients were stratified into three groups (high, mid, low) according to serum VEGF-C, VEGF-D, and VEGF-A concentrations measured before immunotherapy. Groups were compared using a nonparametric Spearman’s test for correlations, two-tailed Student’s t test for dot plots (*P < 0.05), and log-rank (Mantel-Cox) test for survival curves. Manuel Fankhauser et al., Sci Transl Med 2017;9:eaal4712 Published by AAAS